The United States Food and Drug Administration (FDA) has approved daraxonrasib — sold under the brand name Rasonque — for the treatment of advanced pancreatic cancer, marking what doctors and researchers are calling a paradigm shift in tackling one of medicine's most stubbornly lethal diseases. Manufactured by Revolution Medicines, the once-daily pill nearly doubled average survival time in a late-stage clinical trial of 500 patients: those taking daraxonrasib survived an average of 13.2 months, compared to 6.6 months for patients on standard chemotherapy. The FDA approved the drug six months ahead of its regulatory deadline, citing